Dr. Salari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit St., GRB-1109A
Boston, MA 02114
Summary
- Dr. Keyan Salari is a urologic oncologist in Boston, MA and is affiliated with Massachusetts General Hospital and Harvard Medical School. He received his medical degree from Stanford University School of Medicine and trained at Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center. He has been in practice 7 years. He is experienced in urology, oncology, and cancer genomics.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2018 - 2019
Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2014 - 2018- Massachusetts General HospitalInternship, Surgery, 2012 - 2013
Stanford University School of MedicineClass of 2012, M.D.
Stanford UniversityPh.D., Genetics, 2010
University of California, BerkeleyB.A., Molecular and Cell Biology, 2004
Certifications & Licensure
MA State Medical License 2012 - 2026
ME State Medical License 2020 - 2026
RI State Medical License 2021 - 2026
NH State Medical License 2021 - 2025
NY State Medical License 2017 - 2019- American Board of Urology Urology
Publications & Presentations
PubMed
- Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prosta...Andrew E Amini, Alexandra E Hunter, Aya Almashad, Aileen J Feng, Neel D Patel
European Urology Oncology. 2024-12-01 - Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management.Sophia Y Chahine, Khalid Y Alkhatib, Gevorg Arakelyan, Claire Buxton, Gianluca Giannarini
European Urology Focus. 2024-08-14 - Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.Florian Rumpf, Anna Plym, Jane B Vaselkiv, Kathryn L Penney, Mark A Preston
The Journal of Urology. 2024-06-01
Journal Articles
- Detection of Pathogenic Variants with Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients with Prostate Cancer and MelanomaKeyan Salari, MD, JAMA
Press Mentions
Genomic Urine Test Detects Bladder Cancer from DNA up to 12 Years Before Clinical Signs and Symptoms AppearMay 1st, 2023- Role of HRD in Early-Stage Prostate CancerMay 31st, 2022
- Metabolic Syndrome Post-Prostatectomy Ups Prostate Cancer Death RiskSeptember 12th, 2021
- Join now to see all
Professional Memberships
- American Urological AssociationMember
Other Languages
- Spanish, Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
